EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOMYG00000015610
Gene Symbol: HTR5A
1 Cross references
203 Possible Orthologues:

60s Ribosomal Protein L11

Ensembl ID : ENSOMYG00000039361
Gene Symbol: RL11
2 Cross references
282 Possible Orthologues:

60s Ribosomal Protein L15

Ensembl ID : ENSOMYG00000009997
Gene Symbol: RL15
2 Cross references
352 Possible Orthologues:

60s Ribosomal Protein L17

Ensembl ID : ENSOMYG00000041369
Gene Symbol: RL17
2 Cross references
705 Possible Orthologues:

60s Ribosomal Protein L21

Ensembl ID : ENSOMYG00000012541
Gene Symbol: RL21
2 Cross references
778 Possible Orthologues:

60s Ribosomal Protein L28

Ensembl ID : ENSOMYG00000038358
Gene Symbol: RL28
1 Cross references
279 Possible Orthologues:

60s Ribosomal Protein L31

Ensembl ID : ENSOMYG00000038013
Gene Symbol: RL31
3 Cross references
634 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMYG00000041997
Gene Symbol: ARAF
1 Cross references
184 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMYG00000020464
Gene Symbol: ARAF
1 Cross references
184 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000027335
Gene Symbol: ABL1
1 Cross references
196 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000039096
Gene Symbol: ABL1
1 Cross references
196 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOMYG00000007729
Gene Symbol: ADAM17
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).